Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema.

Next Previous
Search
Trial Profile

A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of iCo-007 Intravitreal Injection in Subjects With Diffuse Diabetic Macular Edema.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ICO-007 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors iCo Therapeutics

Most Recent Events

  • 21 Mar 2012 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
  • 18 May 2010 Status changed from active, no longer recruiting to completed, as results have been reported in an iCo Therapeutics media release
  • 18 May 2010 The primary endpoint, ocular safety and tolerability, has been met, according to an iCo Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top